WCLC

Beyond's analysis on WCLC

• 2026-09-12 — SystImmune’s Phase 1 data for Iza-bren show promising activity in EGFR‑mutated lung cancer, backing a 2.5 mg/kg dose for Phase 3

Recent news mentioning WCLC

• 2026-09-12 — SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026
• 2026-08-21 — AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
• 2026-08-21 — Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
• 2026-08-04 — Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Appears alongside

• SystImmune
• AbbVie
• ESMO

Browse the full archive →